COCH vs WST

For growth investors, Envoy Medical, Inc.

(COCH) is the stronger pick with 7. 1% revenue growth year-over-year, versus 6. 3% for West Pharmaceutical Services, Inc. (WST). West Pharmaceutical Services, Inc. (WST) offers the better valuation at 47. 3x trailing P/E (37. 8x forward), making it the more compelling value choice. Analysts rate West Pharmaceutical Services, Inc. (WST) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, West Pharmaceutical Services, Inc.

(WST) delivered a total return of -2. 4%, compared to -93. 2% for Envoy Medical, Inc. (COCH). Over 10 years, the gap is even starker: WST returned +367. 1% versus COCH's -93. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), West Pharmaceutical Services, Inc.

(WST) is the lower-risk stock at 0. 91β versus Envoy Medical, Inc. 's 0. 95β — meaning COCH is approximately 5% more volatile than WST relative to the S&P 500.

By revenue growth (latest reported year), Envoy Medical, Inc.

(COCH) is pulling ahead at 7. 1% versus 6. 3% for West Pharmaceutical Services, Inc. (WST). On earnings-per-share growth, the picture is similar: Envoy Medical, Inc. grew EPS 17. 4% year-over-year, compared to 1. 6% for West Pharmaceutical Services, Inc.. Over a 3-year CAGR, WST leads at 2. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

West Pharmaceutical Services, Inc.

(WST) is the more profitable company, earning 16. 1% net margin versus -98. 6% for Envoy Medical, Inc. — meaning it keeps 16. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WST leads at 20. 1% versus -92. 4% for COCH. At the gross margin level — before operating expenses — WST leads at 35. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

All stocks in this comparison pay dividends.

Envoy Medical, Inc. (COCH) offers the highest yield at 14. 1%, versus 0. 3% for West Pharmaceutical Services, Inc. (WST).

For long-horizon retirement investors, Envoy Medical, Inc.

(COCH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95), 14. 1% yield). Both have compounded well over 10 years (COCH: -93. 5%, WST: +367. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: COCH is a small-cap income-oriented stock; WST is a mid-cap quality compounder stock. COCH pays a dividend while WST does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.